• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Physician-Public Health Practitioners Needed

Publication
Article
MHE PublicationMHE April 2022
Volume 32
Issue 4

A new kind of specialist is needed at academic medical centers to cope with public health emergencies such as the COVID-19 pandemic: physician-public health practitioners.

A new kind of specialist is needed at academic medical centers to cope with public health emergencies such as the COVID-19 pandemic, argued the authors of an opinion piece in JAMA Health Forum in March.

These “physician-public health practitioners” would be trained in how to build partnerships with community organizations, translate scientific information and provide technical assistance to outsider organizations, wrote Kirsten Bibbins-Domingo, Ph.D., M.D., M.A.S., and Alicia Fernandez, M.D., of the University of California, San Francisco, School of Medicine.

As Bibbins-Domingo and Fernandez note, many academic medical centers have ventured into population health with its focus on prevention and broader issues affecting people’s health status, including upstream, social determinants. In some cases, those population health efforts and programs have led to formal and informal partnerships with community organizations and departments of health.

“These movements in academic medical centers are laudable and, based on our experience, argue for more formal training and recognition of the academic physicians who are leading and partnering with others to advance population health,” they argued.

Bibbins-Domingo and Fernandez point to the 1910 Flexner report as putting U.S. medical school on the path toward research excellence and “enshrinement of the biomedical model of clinical care.” Another Flexner-like overhaul of American medical schools is not in the offing, but they say in light of the 21st century healthcare challenges — they mention obesity, the opioid epidemic and infectious diseases — it is time to invest in another kind of academic clinical leader.

Related Videos
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
Related Content
© 2024 MJH Life Sciences

All rights reserved.